<DOC>
	<DOCNO>NCT02936635</DOCNO>
	<brief_summary>The purpose study ass long-term safety tolerability tirasemtiv patient ALS .</brief_summary>
	<brief_title>A Study Patients Who Completed VITALITY-ALS ( CY 4031 )</brief_title>
	<detailed_description>Enrolled participant begin dose tirasemtiv 125 mg twice daily ( 250 mg/day ) period 4 week titrate tolerate dose , maximum dose 250 mg twice daily ( 500 mg/day ) . This study also compare clinical course patient complete treatment tirasemtiv CY 4031 complete treatment placebo CY 4031 continue treatment group tirasemtiv CY 4033 , compare clinical course patient complete treatment tirasemtiv CY 4031 study clinical course continue treatment tirasemtiv CY 4033 , compare clinical course patient complete treatment placebo CY 4031 study clinical course treatment tirasemtiv CY 4033 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Able comprehend willing sign Informed Consent Form ( ICF ) . If verbal consent give , Legal Designee patient must sign ICF form Completed participation study drug FollowUp Visit CY 4031 study Male patient , vasectomy AND confirm zero sperm count , must agree duration participation study either : Use condom sexual intercourse female partner childbearing potential AND female partner use highly effective mean contraception OR Abstain sexual intercourse participation study Female patient postmenopausal ( â‰¥ 1 year ) sterilize , must : Not breastfeed Have negative pregnancy test Have intention become pregnant participation study AND Practice sexual abstinence , define refrain intercourse duration study OR male partner vasectomize confirm zero sperm count , require use condom AND use highly effective contraceptive measure Has diaphragm pace system ( DPS ) study entry anticipate DPS placement course study Has take investigational study drug ( tirasemtiv ) prior dose , within 30 day five halflives prior agent , whichever great Use tizanidine theophyllinecontaining medication study participation Participation planning participate form stem cell therapy treatment ALS another investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>tirasemtiv</keyword>
</DOC>